{"schema_version":"secwatch.filing_event.v1","accession":"0001708599-25-000023","form_type":"8-K","ticker":"SER","cik":"0001708599","company_name":"Serina Therapeutics, Inc.","filed_at":"2025-03-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.529725+00:00","generated_at":"2026-05-24T06:42:53.548274+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Serina presents non-immunogenic POZ-lipid data at ACS 2025 meeting","bullets":["Randall Moreadith, M.D., Ph.D., Chief Development Officer, presented at ACS Spring 2025 in San Diego.","Presentation titled 'A Non-Immunogenic LNP for Gene Delivery: Characterization of Poly(oxazoline) Lipid Nanoparticles'.","In rats, POZ-lipid did not trigger IgM or IgG antibody response after repeat dosing.","In contrast, PEG-lipid standards elicited a strong and boosted antibody response.","Non-immunogenic POZ-lipid could enable safer LNP formulations for gene therapy and RNA medicines."],"urls":{"canonical":"https://secwatch.observer/filing/0001708599-25-000023","json":"https://secwatch.observer/filing/0001708599-25-000023.json","markdown":"https://secwatch.observer/filing/0001708599-25-000023.md","text":"https://secwatch.observer/filing/0001708599-25-000023.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708599/000170859925000023/0001708599-25-000023-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708599/000170859925000023/ser-20250324.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T06:42:53.548274+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}